Generic Name and Formulations:
Beractant (as phospholipids) 25mg/mL; susp for intratracheal administration; preservative-free.
Indications for SURVANTA:
Prevention and treatment of respiratory distress syndrome (RDS) in premature infants.
See literature for dosing chart, administration, and additional support procedures. 100mg of phospholipids (4mL)/kg birth weight per dose, by intratracheal administration; max 4 doses, at 6-hr intervals in the first 48hrs after birth. Rescue: give 1st dose as soon as possible after infant is placed on mechanical ventilation for treatment of RDS. Prevention: give 1st dose as soon as possible after birth, preferably within 15 mins. Avoid suctioning for 1 hour after treatment, unless significant airway obstruction occurs. Retreatment is determined by continued respiratory distress. Get radiographic confirmation of RDS in those infants given preventative dose before giving additional doses.
Interrupt dosing if bradycardia or oxygen desaturation occurs; treat; resume after stabilization. Monitor oxygenation, carbon dioxide, and clinical condition frequently and carefully.
Dosing procedure reactions including oxygen desaturation and bradycardia, rales, moist breath sounds, sepsis, intracranial hemorrhage.
Vials (4mL, 8mL)—1
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Risk for Hypoglycemia During Titration With Insulin Glargine 100 U/mL in T2D
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally